Email ID
Password
Sign me in automatically next time
28 January 2012

An out-of-date US federal structure unable to strategically respond to the innovation challenges of the global economy and a lack of government R&D efforts to make the most of basic and applied research generated at US universities are just some of the barriers that are inhibiting the nation's ability to compete in the 21st century, the Washington think tank Center for American Progress insisted last week. But with the push to trim US spending on a collision course with the need to boost the nation's science and economic competitiveness, Congress and President Obama must figure out a way to reconcile the two in a climate where getting "more bang for the buck" is no longer good enough, CAP said in releasing a series of recommendations, which it predicted are "sure to spark deep resistance in Washington". Plus: White House touts health reform progress; Lawmaker scolds FDA over Novartis drug mix-up; and Democratic leaders seek answers on ADHD shortages. - Read more

 
Amgen has collaborated with Micromet on its BiTE novel oncology platform since last July and it obviously has liked what it has seen, and then in December it ...
Spain appears to be spiralling even further into debt with the pharmaceutical industry as it continues to delay payments to industry. It now owes pharma €6.4 ...
Indian drug maker Ranbaxy will be banned from manufacturing drugs at certain plants for the US market and for the President's Emergency Plan for AIDS Relief ...
Celgene is to acquire Avila Therapeutics, a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein ...
 
Gene sequencing specialist Illumina has launched a "poison pill" defence against Roche's attempted hostile takeover by adopting a shareholders' rights agreement that will serve to dilute the ...
Abbott is to cut around 100 pharmaceutical manufacturing jobs at its Barceloneta site in Puerto Rico, as part of a broader round of cuts mainly affecting its stent manufacturing operations. The ...
GlaxoSmithKline appears keen to deepen its talent pool from the emerging markets as it builds its business there. The UK multinationalhas put in place an initiative to develop its workforceto match ...
Baxter International posted solid fourth-quarter results, with worldwide group revenue rising 3% to $3.59 billion. The firm's medical products division grew 3% to $2.01 billion, while sales in its ...
 
Boehringer Ingelheim is progressing its head and neck cancer programme with the start of two global Phase III trials for its irreversible EGFR inhibitor, afatinib, investigating the product in ...
The US FDA has declined to approve a new indication for two Merck & Co products, Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe), because the study submitted to the agency did not assess the ...
GlaxoSmithKline 's BPH treatment Avodart (dutasteride) could be a beneficial adjunctive treatment for men with low-risk prostate cancer who choose active surveillance over standard treatments, a new ...
Tuebingen, Germany-based Immatics biotechnologies has reported positive Phase II results for its therapeutic cancer vaccine, IMA910, in patients with advanced colorectal cancer (CRC), which the ...
 
The UK's Human Genomics Strategy Group (HGSG), established as part of the UK government's response to the 2009 House of Lords Inquiry into genomic medicine, has made a series of recommendations that ...
With the US FDA's blessing of LEO Pharma's topical gel Picato (ingenol mebutate), patients with actinic keratosis, a precancerous condition, which may progress to a nonmelanoma form of skin cancer, ...
The US FDA has approved UCB 's anti-epileptic Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age ...
The European Commission (EC) has approved an extended indication for Merck Serono 's Rebif (interferon beta-1a), allowing its use in patients with early multiple sclerosis (MS), in line with an ...
 
Sirona Biochem names Sean Cunliffe CEO and director Sirona Biochem, a biotech developing diabetes therapeutics and cancer vaccine antigens, has named ...
Cleveland BioLabs reorganises management as CEO Fonstein steps down Cancer drug discovery and development company Cleveland BioLabs has appointed its COO, Dr Yakov ...
Bill Gates pledges $750m to Global Fund after Kazatchkine steps down Microsoft chair Bill Gates has pledged $750 million to the Global Fund to Fight AIDS , after its ...

Dimebon (latrepirdine) is dead. It didn’t come as much of a shock when Pfizer and Medivation ...

The oblivion of ignoring the obvious
26 January 2012

Several very large pharmaceutical companies each of which boasts a long history of competence in ...

Germany: Orphan drug manufactures beware of the AMNOG 16 November 2011

Get the Flash Player to see this player.

It’s finally here. For a while, a dark cloud has been looming ominously over the industry and, on ...
With rising trial costs and shrinking budgets, pharma companies are working more diligently than ...
Four years ago, Scrip 100 surveyed a broad and representive sample of those working in the ...

After a decade as an officer in the British Royal Marines, Charles Toomey was well prepared for ...

Scrip 100
30 December 2011
Scrip Intelligence has launched the latest Scrip 100, its annual look at the performance and ...

Top-line data show that the once-hyped drug Dimebon (latrepirdine) has again failed to improve ...

EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36